97056 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
Fusion immunomodulatory proteins and methods for making same
#902Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
#903Dual PDGF/VEGF antagonists
#904Insulin-like growth factor 2 (IGF2) binding agents
#905Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4 antibody
#906Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof
#907Method for treating myelofibrosis comprising administering a transforming growth factor beta type II receptor antagonist
#908Compositions and methods for treating pulmonary hypertension
#909Tumor-selective CTLA-4 antagonists
#910Identification of novel anti-fibrotic peptide in C-terminal region of the MET receptor tyrosine kinase
#911BI-SPECIFIC TARGETED CHIMERIC ANTIGEN RECEPTOR T CELLS
#912Vascular endothelial growth factor receptor targeting peptide-elastin fusion polypeptides
#913Binding-triggered transcriptional switches and methods of use thereof
#914Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
#915Gene therapy methods
#916Methods for treating ulcers in a hemoglobinopathy anemia with a soluble actRIIB polypeptide
#917ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (VEGFR2) ANTIBODIES
#918Truncated Her2 SRM/MRM assay
#919Anti-VEGFR antibody and uses thereof
#920METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND PERICYTE COMPOSITION
#921Transforming growth factor-beta receptor type II fusion polypeptides
#922Compositions and methods for programmable sensing and control through combinatorial molecular interactions
#923BTLA fusion protein agonists and uses thereof
#924Method of treatment of cerebral amyloid angiopathy with P75ECD peptide and/or P75ECD-FC fusion protein
#925Cryptic polypeptides and uses thereof
#926FUSION PROTEINS FOR INHIBITING ANGIOGENESIS
#927METHODS FOR INCREASING THERMOGENIC ADIPOCYTES
#928PD-L1 binding fibronectin type III domains
#929Fusion polypeptides capable of activating receptors
#930Recombinant proteins and their therapeutic uses
#931Therapeutic use of p75NTR neurotrophin binding protein
#932Compositions and Conjugates Comprising an Interleukin and Polypeptides That Specifically Bind TGF-beta
#933VEGF antagonist formulations suitable for intravitreal administration
#934SOLUBLE FGFR3 DECOYS FOR TREATING SKELETAL GROWTH DISORDERS
#935Compositions and Methods for the Intracellular Disruption of VEGF and VEGFR-2 by Intraceptors
#936Immunomodulatory fusion proteins
#937VEGF-binding protein for blockade of angiogenesis
#938Treatment of ocular neovascularization using anti-VEGF proteins
#939Bi-functional arginine-glycine-aspartic acid (RGD) peptides and methods to promote angiogenesis
#940Generating targeted sequence diversity in fusion proteins
#941COMBINATION THERAPY FOR CANCER
#942GROWTH FACTOR ANTAGONISTS FOR ORGAN TRANSPLANT ALLOIMMUNITY AND ARTERIOSCLEROSIS
#943COMPOSITIONS AND COMBINATIONS FOR THE TREATMENT OF ANGIOGENESIS DISEASES AND DISORDERS
#944METHOD FOR PREDICTING THE OUTCOME OF A TREATMENT WITH AFLIBERCEPT OF A PATIENT SUSPECTED TO SUFFER FROM A CANCER BY MEASURING THE LEVEL OF A PLASMA BIOMARKER
#945PINK1 C-terminal domain polypeptide and methods using the same in cancer treatment
#946Identification of immunogenic MHC class II peptides for immune-based therapy
#947Nucleic acids encoding bispecific antibodies binding to beta-Klotho and fibroblast growth factor receptor 1
#948HER1 ANTIGEN BINDING PROTEINS BINDING TO THE BETA-HAIRPIN OF HER1
#949HER3 antigen binding proteins binding to the beta-hairpin of HER3
#950Vaccines against HER3 antigens and methods of using the same
#951Method for producing an ActRIIB-Fc fusion polypeptide
#952Binding-triggered transcriptional switches and methods of use thereof
#953Variant activin receptor
#954Nucleic acids encoding hemojuvelin fusion proteins and uses thereof
#955Epidermal growth factor receptor targeted/immunomodulatory fusion proteins and methods of use for them
#956Methods and materials for generating CD8T cells having the ability to recognize cancer cells expressing a HER2/neu polypeptide
#957Methods of making nucleic acid molecules encoding modified chimeric polypeptides with improved pharmacokinetic properties
#958Codon optimization for titer and fidelity improvement
#959Compositions and methods for treating pulmonary hypertension
#960Mutant smoothened and methods of using the same
#961Compositions for regulating iron homeostasis and methods of using same
#962Soluble alpha klotho and serum albumin fusion protein
#963FUSION PROTEINS AND METHODS THEREOF
#964EGFR binding proteins
#965Recombinant self-assembling protein comprising target-oriented peptide and use thereof
#966Compositions and methods for tumor transduction
#967METHODS AND COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE TO EGFRVIII
#968Method and compositions for cellular immunotherapy
#969ANTAGONISTS OF ACTRIIB AND USES FOR INCREASING RED BLOOD CELL LEVELS
#970Somatostatin receptor-based cancer therapy
#971TARGETED TGFß INHIBITION
#972Methods and compositions related to modulators of eukaryotic cells
#973Short peptide-based therapeutic agent and medicinal composition including the same for inhibiting activities of cancer cells
#974FGFR1 EXTRACELLULAR DOMAIN COMBINATION THERAPIES
#975CD33 specific chimeric antigen receptors
#976Fusion protein comprising a ligand binding domain of VEGF and PDGF
#977Multispecific and multifunctional molecules and uses thereof
#978Cysteine engineered fibronectin type III domain binding molecules
#979Method of manufacturing VEGF antagonist fusion proteins
#980Compositions and methods for T cell delivery of therapeutic molecules
#981CS1 targeted chimeric antigen receptor-modified T cells
#982Activin-ActRII antagonists and uses for treating anemia
#983MONOCLONAL AND OLIGOCLONAL ANTI-EGFR ANTIBODIES FOR USE IN THE TREATMENT OF TUMORS EXPRESSING PREDOMINANTLY HIGH AFFINITY EGFR LIGANDS OR TUMORS EXPRESSING PREDOMINANTLY LOW AFFINITY EGFR LIGANDS
#984COMPOSITIONS AND METHODS OF TREATING TUMORS
#985ALK1 RECEPTOR AND LIGAND ANTAGONISTS AND USES THEREOF
#986Ligand binding molecules and uses thereof
#987COMPOSITIONS AND METHODS OF TREATING DISEASE WITH FGFR FUSION PROTEINS
#988WNT ANTAGONISTS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF WNT-MEDIATED DISORDERS
#989Fusion polypeptide capable of binding simultaneously to VEGF-C and VEGF-D
#990Nucleic acids encoding fusion proteins comprising PDGF and VEGF binding portions and methods of using thereof
#991HLA-DR binding peptides and their uses
#992Immunotherapy against ErbB-3 receptor
#993Method of Identifying Transmembrane Protein-interacting Compounds
#994Treatment of cancer using GFR α-4 chimeric antigen receptor
#995Methods of treating liver conditions using Notch2 antagonists
#996Angiopoietin 2, VEGF dual antagonists
#997Auto-active and intracellular mutant of MET
#998ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND USES THEREOF
#999ALK7 ANTAGONISTS AND USES THEREOF
#1000Human Notch1 decoys
#1001EGFR and c-Met fibronectin type III domain binding molecules
#1002Vascular endothelial growth factor fusion protein
#1003Treatment of cardiovascular disease using ActRII ligand traps
#1004Methods of treating cervical cancer
#1005COMPOSITIONS AND METHODS FOR MODULATING BODY WEIGHT
#1006Methods for treating vascular eye disorders with actrii antagonists
#1007Compositions and methods for treating and preventing inflammation
#1008Cancer vaccine compositions and methods of use thereof
#1009Engineered FGF compositions and methods of use thereof
#1010Anti-cancer compositions containing Wnt decoy receptor
#1011Methods for increasing red blood cell levels and treating ineffective erythropoiesis
#1012Transgene genetic tags and methods of use
#1013Vascular endothelial growth factor antagonists and methods of making
#1014Compositions and methods for tumor transduction
#1015Method of treating cancer based on identifying mutations in the extracellular domain III of epidermal growth factor receptor gene
#1016Blood glucose lowering compound
#1017Targeted/TGF-ßRII fusion proteins and methods for making same
#1018Pre-Filled Plastic Syringe Containing a VEGF Antagonist
#1019PANCREATIC CANCER TARGETS AND USES THEREOF
#1020Antibodies with high affinity for alpha-Klotho
#1021Human monoclonal antibodies against EPHA4 and their use
#1022Expression Vector Comprising a Polynucleotide Encoding a Modified Glutamine Synthetase and a Method for Preparing a Target Protein Employing the Same
#1023Anti-PDGFR-beta antibodies and uses thereof
#1024Delivery of therapeutic agents by a collagen binding protein
#1025HUMAN FGFR2C EXTRACELLULAR PROTEIN AS WELL AS CODING GENE AND APPLICATION THEREOF
#1026Use of a VEGF antagonist to treat angiogenic eye disorders
#1027Formulated Receptor Polypeptides and Related Methods
#1028Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor
#1029ACTIVIN-ACTRIIA ANTAGONISTS AND USES FOR TREATING MULTIPLE MYELOMA
#1030Methods of treating cancer by administering IGF-IR binding molecules
#1031Peptides and combination of peptides for use in immunotherapy against various cancers
#1032Peptides and combination of peptides for use in immunotherapy against various cancers
#1033Peptides and combination of peptides for use in immunotherapy against various cancers
#1034Peptides and combination of peptides for use in immunotherapy against various cancers
#1035Peptides and combination of peptides for use in immunotherapy against various cancers
#1036Peptides and combination of peptides for use in immunotherapy against various cancers
#1037NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS
#1038Isolated nucleic acid molecules encoding stabilized receptor polypeptides and uses thereof
#1039Cancer targeting by anti-EGFR peptides and applications thereof
#1040Breast and ovarian cancer vaccines
#1041Diagnosis of cancer by detecting auto-antibodies against vascular endothelial growth factor receptor (VEGFR)
#1042Isolation and use of solid tumor stem cells
#1043Fibronectin based scaffold proteins having improved stability
#1044TGFß TYPE II-TYPE III RECEPTOR FUSIONS
#1045Peptides and combination of peptides for use in immunotherapy against various cancers
#1046Endothelial-targeted Adenoviral Vectors, Methods and Uses Therefor
#1047Nucleic acids encoding chimeric antigen receptor proteins which bind epidermal growth factor receptor and T lymphocyte expressing the protein
#1048Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#1049Truncated epiderimal growth factor receptor (EGFRt) for transduced T cell selection
#1050Human FGFR2B extracellular domain and nucleic acid for coding same
#1051Drug regulated transgene expression
#1052Methods for treating cancer with EGFR nanobodies linked to DR5 binding moieties
#1053Method of promoting bone growth by an anti-actriia antibody
#1054ACTIVIN-ACTRIIA ANTAGONISTS AND USES FOR TREATING OR PREVENTING BREAST CANCER
#1055Novel Method
#1056IL-8 level based method of predicting the outcome of colon cancer treatment
#1057USE OF TGF-BETA ANTAGONISTS OF TREAT TYPE-2 DIABETES
#1058HER2 antigenic polypeptide compositions, and methods for their use in treatment and prevention of carcinomas
#1059Bispecific chimeric antigen receptors and methods of use thereof to treat cancer
#1060Methods of cancer therapy by inhibiting fusion polypeptides comprising fibroblast growth factor receptor 2 (FGFR2) and vinculin (VCL)
#1061AAV vectors for retinal and CNS gene therapy
#1062Polypeptide binding to extracellular domain of epidermal growth factor receptor
#1063METHODS AND FORMULATIONS FOR TREATING VASCULAR EYE DISEASES
#1064Antibodies specific for sulfation sites of sclerostin
#1065INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR
#1066HPV vaccines and methods of use thereof
#1067Breast cancer vaccines and methods of use thereof
#1068Variants derived from ActRIIB and uses therefor
#1069INDIVIDUALIZED TREATMENT OF EYE DISEASE
#1070Compositions comprising angiogenic factors and methods of use thereof
#1071Biomolecule-releasing cell and selection thereof by means of a surface protein
#1072Ligands modified by circular permutation as agonists and antagonists
#1073Nucleic acid construct for making a genetically modified rodent with an inducible ACVR1 mutation that causes ectopic bone formation
#1074Composition comprising branched multipeptide vaccine and vaccine comprising the same
#1075Targeted therapy to restore radioactive iodine transport in thyroid cancer
#1076PDGF receptor beta binding polypeptides
#1077Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof
#1078Growth hormone fusion proteins with growth hormone receptor agonist activity
#1079COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING MACULAR DEGENERATION
#1080Fusion protein inhibiting angiogenesis or growth and use thereof
#1081Peptides and methods and uses thereof for preventing retinal disorders
#1082Stable liquid formulation of fusion protein with IgG Fc domain
#1083Transforming growth factor beta receptor II fusion polypeptides
#1084Methods for treating cancer by inhibiting FGFR3/TACC3 fusion protein
#1085Methods to identify macromolecule binding and aggregation prone regions in proteins and uses therefor
#1086Anti human Notch4 antibody
#1087FGFR-FC fusion proteins and the use thereof
#1088Short peptide-based therapeutic agent and medicinal composition including the same for inhibiting activities of cancer cells
#1089Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#1090THERAPEUTIC USE OF VEGFR-3 LIGANDS
#1091Nucleotide sequences encoding VEGF antagonist compositions of FLT-1 and uses thereof
#1092OPTICALLY ACTIVATED RECEPTORS
#1093Methods of treatment with bispecific antibodies binding to beta-klotho and fibroblast growth factor receptor 1
#1094Isoform of the TGF-beta receptor II
#1095Pharmaceutical compositions targeting WNT pathway proteins
#1096FGFR gatekeeper mutant gene and drug targeting same
#1097Regulatable chimeric antigen receptor
#1098EGFR-based inhibitor peptides for combinatorial inactivation of ERBB1, ERBB2, and ERBB3
#1099Identification of Predictive Biomarkers Associated With WNT Pathway Inhibitors
#1100TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof
#1101ALK7:ActRIIB heteromultimers and uses thereof
#1102Single arm type I and type II receptor fusion proteins and uses thereof
#1103ALK4:ActRIIB heteromultimers and uses thereof
#1104Methods for treating myelodysplastic syndromes and sideroblastic anemias
#1105Methods for treating pulmonary hypertension with a TGF-beta type II receptor-FC fusion protein
#1106Variant activin receptor
#1107DNA VACCINE FOR USE IN PANCREATIC CANCER PATIENTS
#1108VEGF antagonist formulations suitable for intravitreal administration
#1109VEGF specific fusion protein antagonist formulations
#1110Tissue protective peptides and uses thereof
#1111Methods and compositions comprising a combination of a VEGF Trap and an anti-CTLA-4 antibody
#1112Anti-CTLA4 antibody-TGF-βRII targeted/immunomodulatory fusion proteins
#1113Fusion polypeptides comprising mucin-domain polypeptide linkers
#1114c-Met protein agonist
#1115VEGF antagonist formulations suitable for intravitreal administration
#1116ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR ROR1
#1117EPITOPE VACCINE FOR LOW IMMUNOGENIC PROTEIN AND PREPARING METHOD AND USAGE THEREOF
#1118Compositions comprising angiogenic factors and methods of use thereof
#1119FLT4 (VEGFR-3) AS A TARGET FOR TUMOR IMAGING AND ANTI-TUMOR THERAPY
#1120HER2 binders
#1121Method of improving the pharmacokinetic profile of a therapeutic polypeptide and the use thereof
#1122Method for decreasing the body fat content in a subject by administering an ActRIIB protein
#1123FGFR-FC Fusion Proteins and the Use Thereof
#1124Stable VEGF antagonist formulations
#1125Method of treating cancer with an EGFR targeted immunomodulatory fusion protein
#1126Methods and compositions for adoptive cell therapy
#1127NOVEL ACTIVIN RECEPTOR AND USES THEREOF
#1128RECEPTORS FOR B7-H4
#1129Endothelial-targeted Adenoviral Vectors, Methods and Uses Therefor
#1130Human antigen binding proteins that bind β-klotho, FGF receptors and complexes thereof
#1131Isolated nucleic acid molecules encoding stabilized receptor polypeptides and uses thereof
#1132USE OF A VEGF ANTAGONIST IN TREATING CHOROIDAL NEOVASCULARISATION
#1133Antigen binding protein and its use as addressing product for the treatment of cancer
#1134USE OF A VEGF ANTAGONIST IN TREATING MACULAR EDEMA
#1135Modified chimeric polypeptides with improved pharmacokinetic properties
#1136Method of identifying an agent that promotes bone growth or increases bone density
#1137Fusion proteins and methods thereof
#1138Methods of treating mesothelioma by administration of compounds comprising FGFR1 ECD
#1139Use of a VEGF antagonist to treat angiogenic eye disorders
#1140COMPOSITIONS AND METHODS OF TREATING DISEASE WITH FGFR FUSION PROTEINS
#1141A Novel EGFR Variant
#1142Immunosuppressive TGF-β signal converter
#1143Recombinant self-assembling protein comprising target-oriented peptide and use thereof
#1144Methods and compositions for inducing an immune response to EGFRvIII
#1145Modulation of Activity of Proneurotrophins
#1146Syndecan-2 compositions and methods of use
#1147Methods, uses and compositions of Tie2 agonists
#1148Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
#1149METHODS FOR INCREASING RED BLOOD CELL LEVELS AND TREATING INEFFECTIVE ERYTHROPOIESIS
#1150Peptide with gold binding and EGFR receptor affinity and same attached to gold nanostructure
#1151Glycosylated VEGF decoy receptor fusion protein
#1152Method of treating eye disease using glycosylated VEGF decoy receptor fusion protein
#1153Fusion immunomodulatory proteins and methods for making same
#1154Modified soluble VEGF receptor-1 genes and vectors for gene therapy
#1155Fusion molecules and uses thereof
#1156VEGFR-3 ligand binding molecules and uses thereof
#1157HER1 antigen binding proteins binding to the beta-hairpin of HER1
#1158Antibodies against epidermal growth factor receptor (EGFR) and uses thereof
#1159Dual PDGF/VEGF antagonists
#1160MODIFIED T LYMPHOCYTES HAVING IMPROVED SPECIFICITY
#1161Antibodies against epidermal growth factor receptor (EGFR) and uses thereof
#1162Antibodies against epidermal growth factor receptor (EGFR) and uses thereof
#1163Methods of treating cholangiocarcinoma
#1164Soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
#1165Reduction of TGF beta signaling in myeloid cells in the treatment of cancer
#1166VEGF-Aassay
#1167Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof
#1168Angiopoietin-2 specific TIE2 receptor
#1169Methods and compositions related to modulators of eukaryotic cells
#1170HER2Delta16 peptides
#1171FGFR3 fusion gene and pharmaceutical drug targeting same
#1172Sugar chain-attached linker, compound containing sugar chain-attached linker and physiologically active substance or salt thereof, and method for producing same
#1173IGFBP-3 derivatives and uses thereof
#1174Recombinant bi-functional fusion proteins, preparations and methods for treating disease
#1175BMP-ALK3 antagonists and uses for promoting bone growth
#1176HER3 binding polypeptides
#1177Broad spectrum ErBB ligand binding molecules and methods for preparing and using them
#1178Generating targeted sequence diversity in fusion proteins
#1179Anti-HER2 vaccine based upon AAV derived multimeric structures
#1180Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
#1181Methods and materials for generating CD8+ T cells having the ability to recognize cancer cells expressing a HER2/neu polypeptide
#1182Targeted TGFβ inhibitors
#1183Multifunctional nanobodies for treating cancer
#1184Bispecific antibodies binding to beta-klotho and fibroblast growth factor receptor 1
#1185Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis
#1186Antigen peptide derived from the sequence of epidermal growth factor receptor having T790M point mutation
#1187Anti-Her3 scFV fragment and bispecific anti-c-Met/anti-Her3 antibodies comprising the same
#1188Mutated ACVR1 for diagnosis and treatment of Fibrodyplasia Ossificans Progressiva (FOP)
#1189Gene therapy methods
#1190FGFR1 EXTRACELLULAR DOMAIN COMBINATION THERAPIES
#1191ENDOGLIN PEPTIDES TO TREAT FIBROTIC DISEASES
#1192Anti-Tie2 antibodies and uses thereof
#1193Method of treating cancer by administering a monoclonal antibody that binds human NOTCH2 and NOTCH3
#1194Truncated epiderimal growth factor receptor (EGFRt) for transduced T cell selection
#1195Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#1196Antagonists of activin-ActRIIa and uses for increasing red blood cell levels
#1197Vaccine for the prevention of breast cancer relapse
#1198Fusion polypeptides capable of activating receptors
#1199Microvesicles derived from cell protoplast and use thereof
#1200Notch1 receptor binding agents and methods of use thereof